Shine-On BioMedical
  • LANGUAGE
    • 繁體中文
    • English
  • ABOUT
    • Overview
    • Milestone
    • Mission
    • Organization
    • Management and consulting team
  • Core Technologies
    • Targeted exosome for drug delivery
    • Trispecific T cell engager antibody
  • R&D Pipeline
    • Targeted exosome for drug delivery
      • SOB100: HLA-G targeted exosome (αHLA-G exo)
      • SOB101: HLA-G targeted exosomal doxorubicin
      • SOB102: HLA-G targeted exosomal microRNA
      • SOB201: Genetically engineered stem cell-derived exosomes
    • Trispecific T cell engager antibody
      • SOA101: Nanobody-based trispecific antibody T cell engager (Nb-TriTE)
      • SOA201: EphA10-trispecific immune cell engager antibody
    • Exosome-derived products
      • SOC101&SOC102
    • Products Pipeline
  • News
  • Links
    • 政府機構
    • 學術機構
    • 產業新知
  • Investor Zone
  • Sustainable development CSR
    • Sustainable development CSR
    • Ethics compliance and whistleblower protection
  • Stakeholders Area
  • Contact
  • Disclaimer
  • Terms
  • Privacy

R&D Pipeline

  1. HOME
  2. R&D Pipeline
R&D Pipeline
  • Targeted exosome for drug delivery
    • SOB100: HLA-G targeted exosome (αHLA-G exo)
    • SOB101: HLA-G targeted exosomal doxorubicin
    • SOB102: HLA-G targeted exosomal microRNA
    • SOB201: Genetically engineered stem cell-derived exosomes
  • Trispecific T cell engager antibody
    • SOA101: Nanobody-based trispecific antibody T cell engager (Nb-TriTE)
    • SOA201: EphA10-trispecific immune cell engager antibody
  • Exosome-derived products
    • SOC101&SOC102
  • Products Pipeline
  1. Trispecific T cell engager antibody
one two four
  • Nanobody-based trispecific antibody T ce...

    VIEW MORE
    Nanobody-based trispecific antibody T cell engager (Nb-TriTE)
  • Genetically engineered stem cell-derived...

    VIEW MORE
    Genetically engineered stem cell-derived exosomes

04-2327-2888

E-mail : service@shineon-bio.com

Rm. B, 10F., No. 573, Sec. 2, Taiwan Blvd., West Dist., Taichung City 403020, Taiwan

NAVIGATION
  • ABOUT
  • Core Technologies
  • R&D Pipeline
  • News
  • Links
  • Investor Zone
  • Sustainable development CSR
  • Stakeholders Area
  • Contact
  • Disclaimer
  • Terms
  • Privacy
  • HOME
Copyright © 2024 - Shine-On BioMedical Web design : Newscan
TOP
LANGUAGE
  • 繁體中文
  • English
  • ABOUT
    • Overview
    • Milestone
    • Mission
    • Organization
    • Management and consulting team
  • Core Technologies
    • Targeted exosome for drug delivery
    • Trispecific T cell engager antibody
  • R&D Pipeline
    • Targeted exosome for drug delivery
      • SOB100: HLA-G targeted exosome (αHLA-G exo)
      • SOB101: HLA-G targeted exosomal doxorubicin
      • SOB102: HLA-G targeted exosomal microRNA
      • SOB201: Genetically engineered stem cell-derived exosomes
    • Trispecific T cell engager antibody
      • SOA101: Nanobody-based trispecific antibody T cell engager (Nb-TriTE)
      • SOA201: EphA10-trispecific immune cell engager antibody
    • Exosome-derived products
      • SOC101&SOC102
    • Products Pipeline
  • News
  • Links
    • 政府機構
    • 學術機構
    • 產業新知
  • Investor Zone
  • Sustainable development CSR
    • Sustainable development CSR
    • Ethics compliance and whistleblower protection
  • Stakeholders Area
  • Contact
  • Disclaimer
  • Terms
  • Privacy